Rayomand Jal Unwalla

This inventor holds 26 USPTO granted patents and 5 published patent applications, plus 7 CIPO patents and 8 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Pfizer Corporation, Wyeth, Genetics Institute, Inc.. Active years: 2004-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rayomand Jal Unwalla. Retrieved from https://idiyas.com/inventor/rayomand-jal-unwalla

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 5)

% Patents Active = 61.5

CIPO Patents = 7 (Patent Applications = 7)

EPO Patents = 8 (Patent Applications = 9)

Average Co-Inventor Count = 9.2

ph-index = 5

Forward Citations = 103(Granted Patents)

Location History:

Eagleville, PA (US) (2004 - 2010)
Bedford, MA (US) (2015 - 2024)

Company Filing History:

Genetics Institute, Inc.

patents

Years Active: 2004-2026

Loading Chart...

Areas of Expertise:

AMPK Activation

CCR6 Inhibitors

RORC2 Modulators

Toll-Like Receptor Agonists

Pyrrolo Compounds

Androgen Receptor Modulators

Estrogen Receptor

Pharmaceutical Compositions

Cinnoline Compounds

Indazoles

Quinolines

Pyrimidine Derivatives

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12637461 - Compounds for the activation of AMPK (2026-05-26),

2. 12312344 - N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors (2025-05-27),

3. 12077533 - Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides (2024-09-03),

4. 11976064 - Toll-like receptor agonists (2024-05-07),

5. 11708360 - N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors (2023-07-25),

6. 11339159 - Toll-like receptor agonists (2022-05-24),

7. 11111242 - Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides (2021-09-07),

8. 10975065 - N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors (2021-04-13),

9. 10703756 - Pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, pyrrolo[2,3-B]pyridinyl acrylamides and epoxides thereof (2020-07-07),

10. 10426135 - Methyl- and trifluromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof (2019-10-01),

11. 10385036 - Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof (2019-08-20),

12. 10336748 - Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof (2019-07-02),

13. 10328082 - Methods of use and combinations (2019-06-25),

14. 10227346 - Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof (2019-03-12),

15. 9617258 - Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides (2017-04-11),

Title: The Innovative Journey of Rayomand Jal Unwalla in the World of Pharmaceuticals

Introduction:

Rayomand Jal Unwalla, a prolific inventor residing in Bedford, MA (US), has left an indelible mark on the field of pharmaceuticals with his groundbreaking innovations. With an impressive portfolio of 23 patents to his name, Unwalla continues to push the boundaries of science and medicine.

Latest Patents:

Among his latest patents, Unwalla has introduced Toll-like receptor agonists – a revolutionary development in the treatment of abnormal cell growth, particularly in cancer patients. Additionally, his N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides have shown promise as CCR6 inhibitors, offering new possibilities in disease prevention and treatment.

Career Highlights:

With a rich professional background, Unwalla has contributed his expertise to esteemed companies such as Pfizer and Wyeth. His tenure at these organizations has been marked by a relentless pursuit of innovation and a commitment to improving healthcare outcomes for patients globally.

Collaborations:

Throughout his career, Unwalla has had the privilege of collaborating with industry stalwarts like Neelu Kaila and John David Trzupek. Together, they have synergized their talents to drive forward cutting-edge research and development initiatives, setting new benchmarks in the pharmaceutical landscape.

Conclusion:

Rayomand Jal Unwalla's passion for innovation and his unwavering dedication to scientific advancement have cemented his status as a trailblazer in the world of pharmaceutical inventions. His patents stand as a testament to his ingenuity and his relentless pursuit of excellence, inspiring future generations of inventors to push the boundaries of what is possible in the realm of medical science.

Profile summary based on public USPTO records.